|
gptkbp:instanceOf
|
gptkb:drug
antiretroviral therapy
|
|
gptkbp:activeIngredient
|
gptkb:dolutegravir
gptkb:rilpivirine
|
|
gptkbp:approvalYear
|
2017-11-21
|
|
gptkbp:ATCCode
|
J05AR21
|
|
gptkbp:contraindication
|
concurrent use with St. John's wort
concurrent use with carbamazepine
concurrent use with dofetilide
concurrent use with rifampin
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:form
|
gptkb:tablet
fixed-dose combination tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Juluca
|
|
gptkbp:indication
|
HIV-1 infection
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketingAuthorizationHolder
|
gptkb:ViiV_Healthcare
|
|
gptkbp:mechanismOfAction
|
integrase inhibitor and non-nucleoside reverse transcriptase inhibitor
|
|
gptkbp:pregnancyCategory
|
N
|
|
gptkbp:prescribes
|
adults with HIV-1 infection who are virologically suppressed
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
headache
insomnia
|
|
gptkbp:usedIn
|
combination antiretroviral therapy
|
|
gptkbp:bfsParent
|
gptkb:dolutegravir
|
|
gptkbp:bfsLayer
|
6
|